Page 22 - Read Online

Maitland Prostate cancer: from bench to bedside

Trombetta JJ, Lu D, Tallapragada N, Tahirova N, Kim S, Blumenstiel L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers
B, Sougnez C, Lowe A, Wong B, Auclair D, Van Allen EM, CL; Prostate Cancer Foundation/Department of Defense Prostate
Nakabayashi M, Lis RT, Lee GS, Li T, Chabot MS, Ly A, Taplin ME, Cancer Clinical Trials Consortium. Antitumour activity of MDV3100
Clancy TE, Loda M, Regev A, Meyerson M, Hahn WC, Kantoff PW, in castration-resistant prostate cancer: a phase 1-2 study. Lancet
Golub TR, Getz G, Boehm JS, Love JC. Whole-exome sequencing 2010;375:1437-46.
of circulating tumor cells provides a window into metastatic prostate 21. Higano CS, Beer TM, Taplin ME, Efstathiou E, Hirmand M, Forer D,
cancer. Nat Biotechnol 2014;32:479-84. Scher HI. Long-term safety and antitumor activity in the phase 1-2
13. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY, study of enzalutamide in pre- and post-docetaxel castration-resistant
Wang Y, Sheikh KL, Terry S, Tagawa ST, Dhir R, Nelson JB, de la prostate cancer. Eur Urol 2015;68:795-801.
Taille A, Allory Y, Gerstein MB, Perner S, Pienta KJ, Chinnaiyan AM, 22. Butler DE, Marlein C, Walker HF, Frame FM, Mann VM, Simms MS,
Wang Y, Collins CC, Gleave ME, Demichelis F, Nanus DM, Rubin Davies BR, Collins AT, Maitland NJ. Inhibition of the PI3K/AKT/
MA. Molecular characterization of neuroendocrine prostate cancer mTOR pathway activates autophagy and compensatory Ras/Raf/
and identification of new drug targets. Cancer Discov 2011;1:487-95. MEK/ERK signalling in prostate cancer. Oncotarget 2017;8:56698-
14. Beltran H, Prandi D, Mosquera JM, Benelli M, Puca L, Cyrta J, 713.
Marotz C, Giannopoulou E, Chakravarthi BV, Varambally S, Tomlins 23. Ulukaya E, Frame FM, Cevatemre B, Pellacani D, Walker H, Mann
SA, Nanus DM, Tagawa ST, Van Allen EM, Elemento O, Sboner A, VM, Simms MS, Stower MJ, Yilmaz VT, Maitland NJ. Differential
Garraway LA, Rubin MA, Demichelis F. Divergent clonal evolution cytotoxic activity of a novel palladium-based compound on prostate
of castration-resistant neuroendocrine prostate cancer. Nat Med cell lines, primary prostate epithelial cells and prostate stem cells.
2016;22:298-305. PLoS One 2013;8:e64278.
15. Horoszewicz JS, Leong SS, Chu TM, Wajsman ZL, Friedman M, 24. Rane JK, Droop AP, Maitland NJ. A detailed analysis of gene
Papsidero L, Kim U, Chai LS, Kakati S, Arya SK, Sandberg AA. expression in human basal, luminal, and stromal cell populations from
The LNCaP cell line -- a new model for studies on human prostatic benign prostatic hyperplasia tissues and comparisons with cultured
carcinoma. Prog Clin Biol Res 1980;37:115-32. basal cells. Eur Urol 2017;72:157-9.
16. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, 25. Berthon P, Cussenot O, Hopwood L, Leduc A, Maitland N. Functional
Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen expression of sv40 in normal human prostatic epithelial and
CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers fibroblastic cells - differentiation pattern of nontumorigenic cell-lines.
CL. Development of a second-generation antiandrogen for treatment Int J Oncol 1995;6:333-43.
of advanced prostate cancer. Science 2009;324:787-90. 26. Sobel RE, Wang Y, Sadar MD. Molecular analysis and
17. Saad F. Evidence for the efficacy of enzalutamide in characterization of PrEC, commercially available prostate epithelial
postchemotherapy metastatic castrate-resistant prostate cancer. Ther cells. In Vitro Cell Dev Biol Anim 2006;42:33-9.
Adv Urol 2013;5:201-10. 27. Centenera MM, Raj GV, Knudsen KE, Tilley WD, Butler LM. Ex vivo
18. Merseburger AS, Haas GP, von Klot CA. An update on enzalutamide culture of human prostate tissue and drug development. Nat Rev Urol
in the treatment of prostate cancer. Ther Adv Urol 2015;7:9-21. 2013;10:483-7.
19. Cicero G, DE Luca R, Dorangricchia P, Dieli F. The clinical efficacy 28. Fox EJ, Reid-Bayliss KS, Emond MJ, Loeb LA. Accuracy of next
of enzalutamide in metastatic prostate cancer: prospective single- generation sequencing platforms. Next Gener Seq Appl 2014;1: pii:
center study. Anticancer Res 2017;37:1475-80. 1000106.
20. Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, 29. Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current
Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely state of the science. Nat Rev Genet 2016;17:175-88.

270 Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ November 17, 2017